Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DS-1039
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
01
Overview
DS-1039: sourced facts only. name: "In this study, we introduce DS-1039, a novel selective GPR39 agonist, and demonstrate its chloride-inducing activity in airway epithelium." [PMID:41101681]; target: "In this study, we introduce DS-1039, a novel selective GPR39 agonist, and demonstrate its chloride-inducing activity in airway epithelium." [PMID:41101681]; developer: "Asubio Pharma Co., Ltd., 6-4-3 Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan." [PMID:41101681]; stage: "Additionally, DS-1039 caused hyperpolarization in mouse nasal potential difference analysis, an effect that was absent in GPR39-knockout mice." [PMID:41101681]
02
Targets
GPR39 (G protein-coupled receptor 39)
Beyond the preview
Go deeper on DS-1039.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS-1039.